Indications, dosage, and adverse reactions of erdafitinib

Erdafitinib (Erdafitinib) is a selective panFGFR (fibroblast growth factor receptor) inhibitor, mainly suitable for patients with FGFR2 or FGFR3 gene mutations, especially those whose disease has progressed after platinum-containing chemotherapy. The drug inhibits the FGFR signaling pathway and prevents the proliferation and growth of cancer cells, thus exerting anti-tumor effects. Before patients use erdafitinib, they usually need to undergo genetic testing to confirm whether the tumor carries FGFR mutations to determine whether they are suitable for using this drug.

In terms of usage and dosage, the recommended starting dose of erdafitinib is usually 8mg (2 tablets4mg), once a day, if the patient tolerates it well and the serum phosphorus level is within the If it is still below the target range after /span>14 days, the doctor may increase the dose to 9mg (3tablets3mg), once a day. The drug should be taken on an empty stomach or with food, at the same time every day to maintain stable blood concentrations. In addition, erdafitinib may affect serum phosphorus levels, so serum phosphorus concentrations need to be monitored regularly during treatment and the dose adjusted according to the patient's metabolic profile.

Erdafitinib may cause a variety of adverse reactions, the more common of which include hyperphosphatemia, stomatitis, diarrhea, dry skin, nail abnormalities, fatigue, eye discomfort, etc. Among them, hyperphosphatemia is the most important metabolic side effect and may lead to muscle spasms, skeletal abnormalities, or kidney problems, so patients may need to adjust their diet or use phosphate-lowering drugs to manage it. In addition, the drug may cause ocular toxicity, such as blurred vision and retinopathy, so patients are recommended to undergo regular eye examinations before and during treatment to facilitate early detection and treatment of eye discomfort.

Although erdafitinib has certain efficacy in patients with urothelial carcinoma with FGFR mutations, not all patients are suitable for use. Pregnant and lactating women are prohibited from using this drug to avoid potential harm to the fetus or infant. People with severe liver and kidney dysfunction should use it with caution to prevent the drug from accumulating in the body and causing adverse reactions. Patients who are allergic to the drug ingredients are prohibited from using it. In addition, during treatment, if patients experience serious adverse reactions, such as severe hyperphosphatemia, vision loss, or abnormal liver function, dose reduction or medication suspension may be required. Therefore, when using erdafitinib, patients should use it regularly under the guidance of a doctor and closely monitor their physical condition to ensure the safety and effectiveness of the treatment.

Reference link:https://www.balversa.com/